Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 17.81 USD -1.71% Market Closed
Market Cap: 902.4m USD

EV/EBIT
Enterprise Value to EBIT

-18.4
Current
-7.1
Median
16.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-18.4
=
Enterprise Value
605m USD
/
EBIT
-32.8m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
KY
Theravance Biopharma Inc
NASDAQ:TBPH
Average EV/EBIT: 1 878.3
Negative Multiple: -18.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.3
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
34.8
2-Years Forward
EV/EBIT
-27.6
3-Years Forward
EV/EBIT
-27.7